View Press Releases
Almac Discovery to Present at American Association for Cancer Research 2018
CRAIGAVON, N.I., UK - Apr 10, 2018 - Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, is pleased to announce it will present 2 posters during this years AACR Annual Meeting 2018 in Chicago, April 14-18.
Poster details are as follows:
Title: Accessing the cancer DUBome with UbiPlex®: A bespoke drug discovery platform for deubiquitinase enzymes
Session Category: Experimental and Molecular Therapeutics
Session Title: New Targets 1
Session Date and Time: Monday Apr 16, 2018 8:00 AM - 12:00 PM
Location: McCormick Place South, Exhibit Hall A, Poster Section 40
Poster Board Number: 10
Permanent Abstract Number: 1935
Title: Discovery and characterization of highly potent and selective USP7 inhibitors and benchmarking against clinical MDM2 antagonists
Session Category: Experimental and Molecular Therapeutics
Session Title: Novel Targets and Inhibitors
Session Date and Time: Tuesday Apr 17, 2018 1:00 PM - 5:00 PM
Location: McCormick Place South, Exhibit Hall A, Poster Section 39
Poster Board Number: 14
Permanent Abstract Number: 4869
Should you wish to meet with a representative during AACR please contact Martin Wiles, VP Business Development & Licensing - martin.wiles@almacgroup.com.
A copy of both posters will be made available on the Almac Discovery website immediately after the event.